CODEXIS, INC.
Custom engineered enzymes and biocatalysts for RNA and pharmaceutical manufacturing
- Sector
- Biotech
- Headquarters
- REDWOOD CITY, CA
- Latest Form D
- $50M, Jun 2019
- Total capital
- $50M
- Federal grants
- None on recordNo awards found in SBIR/STTR, NIH, NSF or DoD records.
- Private capital raised
- $50M
- 1 Form D · last Jun 2019
- 88 months since last filing
- Federal contracts
- None on recordNo federal contract awards found.
- Granted patents
- 18
- 22 pending · first 2025
- Rank in peer group#3 of 1449
Capital timeline
Latest events
- Private capital raisedForm D · SEC · 1st filing$50M
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Standing among 1449 peers
Line = medianBiotech · Molecule
- Granted patents#3 · top 1%
Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.
Founders and team
From SEC Form D filings- Bernard KelleyDirectorNamed in SEC Form D filings
- Byron DorganDirectorNamed in SEC Form D filings
- David SmithDirectorNamed in SEC Form D filings
- Dennis WolfDirectorNamed in SEC Form D filings
- Gordon SangsterExecutive OfficerNamed in SEC Form D filings
- John NicolsExecutive Officer, DirectorNamed in SEC Form D filings
Show all 10 people
- Kathleen GlaubDirectorNamed in SEC Form D filings
- Pam ChengDirectorNamed in SEC Form D filings
- Patrick YangDirectorNamed in SEC Form D filings
- Thomas BaruchDirectorNamed in SEC Form D filings
What it has protected
USPTO · 18 granted of 40- GrantedEngineered Dna Ligase VariantsUSPTOUS 12,729,376
- PendingEngineered Terminal Deoxynucleotidyl Transferase VariantsUSPTOApplication 19442440
- PendingEngineered Ligase VariantsUSPTOApplication 19202288
Show all 40 patent records
- Engineered Dna Ligase VariantsSep 8, 2026 · US 12,729,376Granted
- Engineered Terminal Deoxynucleotidyl Transferase VariantsAug 20, 2026 · Application 19442440Pending
- Engineered Ligase VariantsAug 13, 2026 · Application 19202288Pending
- Engineered Rnase Inhibitor VariantsJul 30, 2026 · Application 19142170Pending
- Carboxyesterase Polypeptides For Kinetic ResolutionJul 9, 2026 · Application 19571984Pending
- Engineered Transaminase Biocatalysts And Methods For Synthesizing Chiral AminesJun 30, 2026 · US 12,668,824Granted
- Engineered Phosphopentomutase Variant EnzymesJun 30, 2026 · US 12,668,789Granted
- Dna Polymerase VariantsJun 25, 2026 · Application 19127897Pending
- Carboxyesterase Polypeptides For Kinetic ResolutionApr 28, 2026 · US 12,612,605Granted
- Transaminase BiocatalystsMar 19, 2026 · Application 19254921Pending
- Engineered Terminal Deoxynucleotidyl Transferase VariantsMar 3, 2026 · US 12,565,641Granted
- Biocatalysts And Methods For Synthesizing Derivatives Of Tryptamine And Tryptamine AnalogsFeb 26, 2026 · Application 19278336Pending
- Enone ReductasesFeb 12, 2026 · Application 19272475Pending
- Engineered Galactose Oxidase Variant EnzymesFeb 12, 2026 · Application 19366048Pending
- Engineered Sucrose Phosphorylase Variant EnzymesFeb 5, 2026 · Application 19364514Pending
- Peroxidase Activity Towards 10-ACETYL-3,7-DIHYDROXYPHENOXAZINEFeb 3, 2026 · US 12,540,314Granted
- Transaminase PolypeptidesJan 29, 2026 · Application 19352911Pending
- Engineered NitroaldolasesJan 22, 2026 · Application 18868597Pending
- Engineered Phosphopentomutase Variant EnzymesJan 8, 2026 · Application 19328851Pending
- Engineered Imine Reductases And Methods For The Reductive Amination Of Ketone And Amine CompoundsDec 25, 2025 · Application 19317976Pending
- Engineered Transaminase PolypeptidesDec 23, 2025 · US 12,503,688Granted
- Ketoreductase Polypeptides For The Reduction Of AcetophenonesDec 4, 2025 · Application 19306129Pending
- Penicillin-g AcylasesNov 25, 2025 · US 12,480,111Granted
- Engineered Galactose Oxidase Variant EnzymesNov 25, 2025 · US 12,480,099Granted
- Ketoreductase Polypeptides For The Preparation Of PhenylephrineNov 25, 2025 · US 12,480,100Granted
- Engineered Sucrose Phosphorylase Variant EnzymesNov 25, 2025 · US 12,480,104Granted
- Engineered Guanylate Kinase Variant EnzymesNov 18, 2025 · US 12,473,557Granted
- Penicillin-g AcylasesNov 13, 2025 · Application 19276625Pending
- Engineered Imine Reductases And Methods For The Reductive Amination Of Ketone And Amine CompoundsNov 13, 2025 · Application 19237906Pending
- Ketoreductase Polypeptides For The Production Of (R)-3-HYDROXYTHIOLANENov 13, 2025 · Application 19278269Pending
- Engineered Transaminase Polypeptides For Industrial BiocatalysisNov 6, 2025 · Application 19272619Pending
- Engineered Deoxyribose-phosphate AldolasesNov 4, 2025 · US 12,460,195Granted
- Novel P450-BM3 Variants With Improved ActivityOct 23, 2025 · Application 19249225Pending
- Transaminase PolypeptidesOct 21, 2025 · US 12,448,611Granted
- Engineered Transaminase PolypeptidesOct 16, 2025 · Application 19203721Pending
- Engineered Imine Reductases And Methods For The Reductive Amination Of Ketone And Amine CompoundsOct 2, 2025 · Application 19217210Pending
- Engineered Uridine Phosphorylase Variant EnzymesSep 30, 2025 · US 12,428,629Granted
- Polynucleotides Encoding Engineered Imine ReductasesSep 23, 2025 · US 12,421,532Granted
- Polynucleotides Encoding Engineered Acetate Kinase Variant EnzymesSep 23, 2025 · US 12,421,505Granted
- Ketoreductase Polypeptides For The Production Of AzetidinoneSep 23, 2025 · US 12,421,503Granted
Related companies, and why
- IN8BIO, INC.Similar federal contract value in Biotech · null in contracts
- Convergent TherapeuticsSimilar federal contract value in Biotech · null in contracts
- Amylyx Pharmaceuticals, Inc.Similar federal contract value in Biotech · null in contracts
- SurrozenSimilar federal contract value in Biotech · null in contracts
- Clene Nanomedicine, Inc.Similar federal contract value in Biotech · null in contracts
- TNA Therapeutics Inc.Similar federal contract value in Biotech · null in contracts
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .